All News
Pollution and Autoimmunity (7.12.2024)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Read Article
PNAS & Nature Insights into Lupus Pathogenesis
Two prominent medical journals this week published new insights into the pathogenesis of systemic lupus erythematosus (SLE), with both inidicating promient roles for T cells in what is a classically viewed as a humoral (B cell) disorder.
Read Article
Ultraprocessed Foods Increase Lupus Risk
d
MedPage Today
Among women followed for upwards of 25 years, those who ate relatively large amounts of "ultraprocessed" foods -- such as soft drinks, frozen pizzas, and mass-produced baked goods -- developed systemic lupus erythematosus at more than 50% greater rates than those with relatively low consumption, a new analysis of Nurses' Health Study data showed.
Read Article
In the US CorEvitas registry of 1823 PsA pts; 11.1% fulfilled fibromyalgia definition & 20.6% had widespread pain. FM was assoc w/ female, depression/anxiety, impaired function, increased BMI, comorbidities. cDAPSA, patient pain& TJC https://t.co/YwRBYo1aR6 https://t.co/TXraU0F3Mh
Dr. John Cush RheumNow ( View Tweet)
FDA adverse event study of JAKi in #RA assoc w/ signif more VTE, ischemic heart Dz, & tachyarrhythmias. 75,407 on JAKi vs 303,278 on biologics (TNFi, RTX, TCZ); JAK had more VTE (ROR=2.11), CVA (ROR=1.25), IHD (1.23), arrhythmias (1.15 ), esp in 1st yr. https://t.co/IVsGwqpiJK https://t.co/4epOHdNHbO
Links:
Dr. John Cush RheumNow ( View Tweet)
Sobi has submitted a biologics license application to FDA for SEL-212 (pegadricase a uricase enzyme that breaks down uric acid) based on DISSOLVE I & II RCTs. SEL-212 was given FDA FDA’s Fast Track designation in March 2024 https://t.co/TPcUnCJOxT https://t.co/X1DrFDJZeK
Dr. John Cush RheumNow ( View Tweet)
Full read, comprehensive review of NLRP3 inflammasome & its role in inate immunity (eg, infections), but also lifestyle (obesity, diabetes, NAFLD, heart/lung disease, periodontitis) and autoimmune diseases https://t.co/rCk9ncEsGA https://t.co/qc9eSIAVYe
Dr. John Cush RheumNow ( View Tweet)
European Research Council has awarded a Proof of Concept Grant to Institute of Bioengineering of Catalonia and their OrthoBots project, to study the treatment of joint diseases using nanorobots to deliver nanoparticle based therapy to synovial tissues https://t.co/JmYQ1727rf https://t.co/k5uZoSwJPo
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Community-Acquired Pneumonia (CAP)
https://t.co/geb8y2AK26 https://t.co/cB3y5vQoz1
Dr. John Cush RheumNow ( View Tweet)
Progress in SLE with new mRNA CAR-T cell Trial
Cartesian Therapeutics, has announced their first-in-class mRNA CAR-T therapy has been given to the first SLE. patient in a Phase 2 open-label clinical trial.
https://t.co/7SYNtjIn9F https://t.co/a5LJn8QLT3
Dr. John Cush RheumNow ( View Tweet)
Urticarial vasculitis - rare autoimmune dz w/ persistent edematous papules & plaques lasting >24 hrs, w/ systemic Sxs (joint pain, fever). Long-lasting skin lesions tend to leave a bruiselike look. Requires Bx show leukocytoclasticl vasculitis https://t.co/cFWrntrlMw https://t.co/JPkh5FVNo3
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: 2022 EULAR Recommendations on Screening & Prophylaxis for Opportunistic Infections
https://t.co/eHn2o2pFFR https://t.co/8S1fzl4AaJ
Dr. John Cush RheumNow ( View Tweet)
MTX was tapered or D/C in 30% of RA pts w/in 2 yrs of b/tsDMARD Rx. Of 889 pts, MTX (19 mg/wk) tapered in 13.8% & D/C 16.5% (planned taper(37%); pt decision (27.2%). In 582 (66%) MTX unchanged, 4.25 increased MTX after b/tsDMARD initiation https://t.co/yc8exMbeD1 https://t.co/b3L3Fha7xU
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (dual-IL-17A/F inhib), may prevent uveitis in patients with axSpA. In phase 3 RCTs (MOBILE 1 & 2) double-blind period, uveitis seen in 0.6% on BKZ vs 4.6% on PBO (p=0.001). In pts w/ hx uveitis, again lower w/ BKZ (6.2/100 PYs vs 70.4/100 PYs) https://t.co/v0wMK45chz https://t.co/CVPdg1k41V
Dr. John Cush RheumNow ( View Tweet)
PMR - a Risk Factor for Recalcitrant Giant Cell Arteritis?
Despite the clinical similarities and treatment differences between giant cell arteritis (GCA polymyalgia rheumatica (PMR), confusion exists regarding the impact of overlapping disorders.
https://t.co/Slnq68YQgh https://t.co/nCYswGmlCk
Dr. John Cush RheumNow ( View Tweet)
Cost-Effectiveness of Biosimilars vs Leflunomide
An economic evaluation of 25 099 rheumatoid arthritis patients found that treatment with biosimilar DMARDs were cost-effective compared with the conventional DMARD, leflunomide.
https://t.co/lWJB1VL1CL https://t.co/lzra8suVqs
Dr. John Cush RheumNow ( View Tweet)
IV zoledronic acid (ZA) does not prevent future knee replacement (TKR) in symptomatic knee OA without severe joint space narrowing (JSN). In 222 Knee OA pts, after 7 yrs F/U, ZA had more TKR (39% vs 30%; HR 4.2' 1.2-14.7) https://t.co/2cGeqz2Rwu https://t.co/1UiODwQiK6
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Can Mycophenolate be Stopped in Stable SLE?
https://t.co/WJv2CajgW9 https://t.co/AU8X5bVSJQ
Dr. John Cush RheumNow ( View Tweet)
CHANCE-3 DBR-PCT of 8343 adults (>40yrs) w/ CVA or TIA & hsCRP ≥2 mg/L showed that colchicine (0.5mg) x 90d did not prevent (6.3% vs 6.5%; HR 0.98; 0.83 to 1.16) subsequent stroke within 90 days compared with placebo https://t.co/APiMYVkBTV https://t.co/VgFiCKfMqB
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Dead Words Eulogy
https://t.co/kmgWJDMigE https://t.co/raZvkGW4vv
Dr. John Cush RheumNow ( View Tweet)